Alnylam's Cardiovascular siRNA Program Hits Phase 3 Primary Endpoint
The RNA interference pioneer reports positive topline data for its Lp(a)-targeting siRNA in cardiovascular disease, validating oligonucleotide approaches beyond rare disease and into large patient populations.
Apr 5, 2026 · 5 min read